Health, Longevity & Biohacking
MAPS MDMA Therapy Submitted to FDA Could Unlock Psychedelic Industry in 2024
Third Wave Podcast
PSYC’s CEO Provides Detailed Update on the State of the Company
"MAPS's MDMA clinical trial for PTSD using MDMA as a treatment for PTSD, which has been in clinical trials for several years now, was just submitted last month to the FDA for approval. There is a belief that MDMA therapy will be approved by the FDA at some point here in 2024."
Flores revealed that MAPS submitted its MDMA-assisted therapy for PTSD to the FDA for approval last month, with industry insiders believing approval is likely in 2024. This would mark the first FDA-approved psychedelic therapy and establish a regulatory pathway for other psychedelic drugs like psilocybin and LSD currently in clinical trials.
From this episode
Third Wave Podcast